| olanzapine / Generic mfg. |
| Completed | 2a | 106 | US | AZD2624, Olanzapine, Zyprexa, Placebo | AstraZeneca | Schizophrenia | 03/09 | 03/09 | | |
NCT00827918: A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004) |
|
|
| Completed | 2a | 216 | RoW | MK-8998, Comparator: Olanzapine, Comparator: Placebo | Merck Sharp & Dohme LLC | Schizophrenia | 04/10 | 04/10 | | |
NCT03557931: A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication |
|
|
| Completed | 2a | 233 | US | ASP4345, placebo, risperidone, Risperdal, quetiapine, Seroquel, olanzapine, Zyprexa, ziprasidone, Geodon, aripiprazole, Abilify, brexpiprazole, Rexulti, paliperidone, Invega, lurasidone, Latuda | Astellas Pharma Global Development, Inc. | Schizophrenia | 10/19 | 10/19 | | |
CALM 201, NCT05163717: INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD |
|
|
| Terminated | 2a | 8 | US | INP105, POD-OLZ, Placebo, POD-placebo, POD-PBO | Impel Pharmaceuticals | Agitation in Adolescents and Young Adults With ASD | 03/23 | 04/23 | | |
NCT00260962: Olanzapine in the Treatment of Patients With Anorexia Nervosa |
|
|
| Completed | 2 | 34 | Canada | Olanzapine, Zyprexa, Day Hospital | Ottawa Hospital Research Institute, Eli Lilly and Company | Anorexia Nervosa | 07/06 | 09/06 | | |
NCT00149292: Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo |
|
|
| Completed | 2 | 195 | RoW | LY2140023, olanzapine, placebo | Denovo Biopharma LLC | Schizophrenia | 07/06 | 07/06 | | |
NCT00073164: Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia |
|
|
| Completed | 2 | 400 | US | Divalproex Sodium Extended-Release Tablets, Olanzapine, Risperidone | Abbott | Schizophrenia | | | | |
NCT00265551: Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia |
|
|
| Completed | 2 | 300 | US | SCA-136 (200 mg), SCA-136 (400 mg), olanzapine (15 mg), placebo | Wyeth is now a wholly owned subsidiary of Pfizer | Schizophrenia | | 01/07 | | |
NCT00455442: A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain |
|
|
| Completed | 2 | 57 | RoW | Mifepristone | Corcept Therapeutics, Eli Lilly and Company | Weight-Gain Prevention | | 07/07 | | |
| Completed | 2 | 338 | US, Europe, RoW | SB-773812, Olanzapine | GlaxoSmithKline | Schizophrenia | | 08/07 | | |
2006-006184-23: A randomised, double-blind, placebo- and olanzapine- controlled, parallel-group study to evaluate the efficacy and safety of 3 fixed doses of S 33138 in treatment of patients with an acute episode of Schizophrenia. A phase IIb, international, multicentre, 8-week study |
|
|
| Ongoing | 2 | 480 | Europe | S33138, ZYPREXA, S33138, Film-coated tablet, ZYPREXA | Institut de Recherches Internationales Servier | Schizophrenia | | | | |
NCT00428168: Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment |
|
|
| Terminated | 2 | 36 | Canada, RoW | Betahistine | OBEcure Ltd. | Weight Gain | 08/08 | 12/08 | | |
| Completed | 2 | 654 | Europe, RoW | LY2140023, Olanzapine, Placebo | Eli Lilly and Company | Schizophrenia | 10/08 | 10/08 | | |
NCT00734435: Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects |
|
|
| Terminated | 2 | 26 | US | zonisamide SR plus olanzapine, Zyprexa, Placebo plus olanzapine | Orexigen Therapeutics, Inc | Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder | 12/08 | 12/08 | | |
CONNECT, NCT00439634: Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia |
|
|
| Terminated | 2 | 873 | US, Canada | AVE1625, Drinabant, placebo | Sanofi | Schizophrenia | 09/09 | 09/09 | | |
| Completed | 2 | 93 | Europe, RoW | Zicronapine, Lu 31-130, Olanzapine, Zyprexa | H. Lundbeck A/S | Schizophrenia | 10/09 | 11/09 | | |
| Completed | 2 | 498 | Europe, RoW | JNJ-37822681, Olanzapine, Placebo | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 02/10 | 02/10 | | |
|
|
| Completed | 2 | 261 | Europe, US, RoW | LY2140023, pomaglumetad methionil, aripiprazole, Abilify, olanzapine, Zyprexa, risperidone, Risperdal | Denovo Biopharma LLC | Schizophrenia | 05/10 | 12/10 | | |
|
|
| Completed | 2 | 167 | Europe, US, RoW | LY2140023, pomaglumetad methionil, Placebo, Standard of Care | Denovo Biopharma LLC | Schizophrenia | 06/12 | 06/12 | | |
|
| Withdrawn | 2 | 0 | RoW | SCH 900435 (Org 25935), Placebo, Olanzapine, Zyprexa® | Merck Sharp & Dohme LLC | Schizophrenia | 07/12 | 07/12 | | |
| Completed | 2 | 301 | US, Europe, RoW | bitopertin [RO4917838], olanzapine, placebo | Hoffmann-La Roche | Schizophrenia | 09/12 | 09/12 | | |
| Terminated | 2 | 2 | Europe | GWP42003 : GWP42004 (40:1), Placebo | Jazz Pharmaceuticals | Schizophrenia | 10/12 | 10/12 | | |
NCT01323205 / 2010-023369-23: Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia |
|
|
| Completed | 2 | 100 | Europe | JNJ-40411813, Placebo, Antipsychotic medication | Janssen Research & Development, LLC | Schizophrenia | 11/12 | 12/12 | | |
NCT02462473: A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry |
|
|
| Terminated | 2 | 9 | US | Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone | Janssen Research & Development, LLC | Schizophrenia, Schizoaffective Disorder | 01/16 | 01/16 | | |
NCT03319953: A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia |
|
|
| Completed | 2 | 23 | Europe | TAK-041, Placebo, Second Generation Antipsychotics (SGA) | Neurocrine Biosciences, Takeda | Stable Schizophrenia | 09/19 | 11/19 | | |
NCT03960151: Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy |
|
|
| Withdrawn | 2 | 0 | NA | Rolapitant, Varubi, Palonosetron, Aloxi, Olanzapine, Zyprexa, Dexamethasone, steroid | Costantine Albany, Tesaro, Inc. | Germ Cell Tumor | 05/21 | 03/22 | | |
NCT06065722: Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy |
|
|
| Recruiting | 2 | 100 | US | Akynzeo, Olanzapine | Simon Williamson Clinic, Helsinn Healthcare SA | Chemotherapy Induced Nausea and Vomiting | 12/23 | 12/23 | | |
NCT00089869: A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia |
|
|
| Completed | 1/2 | | US | olanzapine, atomoxetine, placebo | Eli Lilly and Company | Schizophrenia | | | | |
